Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Centessa Pharmaceuticals plc - American Depositary Shares (NQ:CNTA)

24.20 +0.06 (+0.27%)
Streaming Delayed Price Updated: 2:08 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Centessa Pharmaceuticals plc - American Depositary Shares

< Previous 1 2 3 4 5 6 Next >
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Olo, Centessa, PayPal, and Opendoor and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Warner Bros., Olo, Centessa, and PayPal and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2022
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Olo, Centessa, PayPal, and Opendoor and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Centessa Pharmaceuticals to Present Additional 18-Months of Continued Treatment Data with SerpinPC from Open-Label Extension of Phase 2a Study at 64th ASH Annual Meeting
New efficacy and safety data from 18-months of continued treatment with subcutaneous doses of SerpinPC in subjects with hemophilia accepted for oral presentation 
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Warner Bros., Olo, Centessa, and PayPal and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Warner Bros., Olo, Centessa, and PayPal and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Barclays, Warner Bros., Olo, and Centessa and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Centessa, PayPal, Opendoor, and Schmitt and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC, A Top Firm, Notifies Centessa Pharmaceuticals plc (CNTA) Investors of Class Action and Encourages Investors to Actively Participate
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
NASDAQ:CNTA Shareholder Notice: Lawsuit Alleges Securities Laws Violations by Centessa Pharmaceuticals Plc
San Diego, CA -- (SBWIRE) -- 10/12/2022 -- An investor, who purchased shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA), filed a lawsuit against Centessa Pharmaceuticals plc over alleged Federal... 
Via SBWire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Centessa, PayPal, Opendoor, and Schmitt and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Centessa and PayPal and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Centessa Pharmaceuticals Plc (NASDAQ:CNTA) Investor Alert: Investigation over Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 10/05/2022 -- An investigation on behalf of investors in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) was announced over potential breaches of fiduciary duties by... 
Via SBWire
INVESTOR NOTICE: Centessa Pharmaceuticals plc Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – CNTA
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Olo and Centessa and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
CENTESSA PHARMACEUTICALS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Centessa Pharmaceuticals plc - CNTA
From Kahn Swick & Foti, LLC
Via Business Wire
Centessa Pharmaceuticals plc Shareholder Update: Robbins LLP Reminds Investors of Class Action Against Centessa Pharmaceuticals plc (CNTA)
From Robbins LLP
Via Business Wire
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Centessa Pharmaceuticals plc with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
CENTESSA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Centessa Pharmaceuticals Plc and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
INVESTOR ALERT: Centessa Pharmaceuticals plc Investors with Substantial Losses Have Opportunity to Lead the Centessa Class Action Lawsuit - CNTA
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Centessa Pharmaceuticals plc (CNTA)
From Robbins LLP
Via Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Centessa Pharmaceuticals plc with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
Important Biotech Catalysts For September 14, 2022 - End Of The Day Summary
 
Via Benzinga
FDA Grants Orphan Drug Status To Centessa's Hemophilia B Candidate
Centessa Pharmaceuticals (NASDAQ: CNTA) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to SerpinPC for the treatment of hemophilia B. A Phase 2a... 
Via Benzinga
Centessa Pharmaceuticals Plc (NASDAQ:CNTA) Shareholder Notice: Investigation over Potential Securities Laws Violations
San Diego, CA -- (SBWIRE) -- 08/23/2022 -- Centessa Pharmaceuticals plc is under investigation concerning possible securities laws violations in connection with certain financial statements. 
Via SBWire
INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Centessa Pharmaceuticals plc with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Centessa Pharmaceuticals plc with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
Morgan Stanley Downgrades Centessa Pharmaceuticals: Here's What You Need To Know
  Morgan Stanley downgraded its rating of Centessa Pharmaceuticals (NASDAQ:CNTA) to Underweight with a price target of $5.00, changing its price target from $10.00 to $5.00. Shares of Centessa... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.